Biomimetic micro-structured hydrogel scaffolds for tissue engineered heart valves

用于组织工程心脏瓣膜的仿生微结构水凝胶支架

基本信息

  • 批准号:
    8250357
  • 负责人:
  • 金额:
    $ 37.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-04-01 至 2015-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Heart valve diseases require hospitalization of more than 90,000 Americans each year, but there are very few options for treating heart valve dysfunction, and even less is known about the mechanisms the underlie valve disease. The essential function of heart valves is made possible by the unique microstructural arrangement of fibrous extracellular matrix proteins within the valve leaflet tissue, but these valvular structure- function relationships have not been translated into the next generation of valve tissue engineering investigations and for in vitro analyses of valvular cell biology and disease. The primary microstructural attributes of aortic valves are their anisotropic nature and their interconnected, layered structure, which provide valvular interstitial cells (VICs) with heterogeneous pericellular environments. These characteristics are not provided by the polymer mesh scaffolds being investigated for tissue engineered heart valves (TEHVs), and there is little consensus about optimal strategies to produce a cellular leaflet scaffolds. Many groups including ours have investigated natural and synthetic gel-based scaffolds for studies of VIC biology and pathology, but these have generally seeded VICs within or atop homogeneous structures. Electrospinning can produce layered structures and anisotropy, but this approach is highly sensitive to operating parameters. We propose to integrate these heterogeneous structure and material characteristics of heart valves into hydrogel biomaterials. Hydrogel biomaterials (particularly poly ethylene glycol diacrylate, PEGDA) are appealing for use as TEHV scaffolds because they have tunable structure and mechanics, can be readily bio- functionalized, and can easily encapsulate cells. Research concerning these materials; however, has generally been focused on their biological activities, as opposed to the development of advanced material behavior. The goal of the proposed work is to apply novel patterning and layering methodologies to generate advanced 3D hydrogels that mimic the complex microstructure and material behavior of aortic valve tissues. We are ideally positioned to generate these materials, having expertise in the characterization of heart valve microstructure, material behavior, and mechanobiology as well as the use of patterning to govern biological ligand presentation and more recently to generate novel structures and regions of differential material behavior within PEGDA hydrogels. These advanced structures will have tremendous impact on the next generation of TEHV scaffolds and could also be used as more faithful biomimetic platforms for 3D investigations of valvular cell biology and disease mechanisms. The following aims will be performed to accomplish this goal: 1. Compare electrospinning, laser printing photolithography, and 2-photon absorption confocal patterning approaches to generate anisotropic hydrogels demonstrating a valve-like biological-shape stress-strain curve. 2. Optimize semi-interpenetrating approaches to develop composite laminate hydrogel scaffolds. 3. Pattern interconnecting structures into the layers of the composite laminate hydrogels. PUBLIC HEALTH RELEVANCE: More than 90,000 Americans each year are hospitalized for heart valve disease, but there are very few options for treating valve disease. In order to grow replacement heart valves, we propose to develop new materials that mimic the complicated interior structure and mechanical behavior of heart valves, and also have the potential to guide normal heart valve cell behavior. These new material structures may also help us understand why ordinarily durable heart valves become diseased.
描述(由申请人提供):心脏瓣膜疾病每年需要超过90,000名美国人住院治疗,但治疗心脏瓣膜功能障碍的选择很少,对瓣膜疾病的潜在机制了解更少。心脏瓣膜的基本功能通过瓣膜小叶组织内纤维细胞外基质蛋白的独特微结构排列而成为可能,但这些瓣膜结构-功能关系尚未转化为下一代瓣膜组织工程研究以及瓣膜细胞生物学和疾病的体外分析。主动脉瓣的主要微观结构属性是其各向异性性质及其相互连接的分层结构,这为瓣膜间质细胞(VIC)提供了异质的细胞周围环境。正在研究的用于组织工程心脏瓣膜(TEHV)的聚合物网状支架没有提供这些特征,并且关于产生细胞小叶支架的最佳策略几乎没有共识。包括我们在内的许多小组已经研究了天然和合成凝胶基支架用于维克生物学和病理学研究,但这些研究通常将VIC接种在均匀结构内或顶部。静电纺丝可以产生层状结构和各向异性,但这种方法对操作参数高度敏感。 我们建议将这些异质结构和材料特性的心脏瓣膜到水凝胶生物材料。水凝胶生物材料(特别是聚乙二醇二丙烯酸酯,PEGDA)吸引人用作TEHV支架,因为它们具有可调的结构和力学,可以容易地生物功能化,并且可以容易地包封细胞。然而,关于这些材料的研究通常集中在它们的生物活性上,而不是先进材料行为的发展。 拟议工作的目标是应用新的图案化和分层方法来生成先进的3D水凝胶,以模拟主动脉瓣组织的复杂微观结构和材料行为。我们的理想定位是生成这些材料,在心脏瓣膜微观结构,材料行为和机械生物学的表征以及使用图案化来管理生物配体呈现方面具有专业知识,最近在PEGDA水凝胶内生成新的结构和差异材料行为区域。这些先进的结构将对下一代TEHV支架产生巨大的影响,也可以用作更忠实的仿生平台,用于瓣膜细胞生物学和疾病机制的3D研究。为实现这一目标,将采取以下措施:1.比较静电纺丝、激光印刷光刻和双光子吸收共聚焦图案化方法,以生成各向异性水凝胶,展示瓣膜状生物形状的应力-应变曲线。2.优化半互穿方法以开发复合层压水凝胶支架。3.将互连结构图案化到复合层压水凝胶的层中。 公共卫生相关性:每年有超过90,000名美国人因心脏瓣膜疾病住院,但治疗瓣膜疾病的选择很少。为了培育替代心脏瓣膜,我们建议开发新材料,模拟心脏瓣膜复杂的内部结构和机械行为,并有可能指导正常的心脏瓣膜细胞行为。这些新的材料结构也可以帮助我们理解为什么通常耐用的心脏瓣膜会患病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KATHRYN JANE GRANDE-ALLEN其他文献

KATHRYN JANE GRANDE-ALLEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KATHRYN JANE GRANDE-ALLEN', 18)}}的其他基金

Differential Shear Forces on Endocardial Endothelial Cells Regulate a Fibrotic Spectrum in the Left Ventricular Outflow Tract
心内膜内皮细胞上的差异剪切力调节左心室流出道中的纤维化谱
  • 批准号:
    10170409
  • 财政年份:
    2018
  • 资助金额:
    $ 37.11万
  • 项目类别:
Engineering MicroEnvironment Core (EMEC)
工程微环境核心 (EMEC)
  • 批准号:
    10192207
  • 财政年份:
    2015
  • 资助金额:
    $ 37.11万
  • 项目类别:
Engineering MicroEnvironment Core (EMEC)
工程微环境核心 (EMEC)
  • 批准号:
    10642942
  • 财政年份:
    2015
  • 资助金额:
    $ 37.11万
  • 项目类别:
Engineering MicroEnvironment Core (EMEC)
工程微环境核心 (EMEC)
  • 批准号:
    10462790
  • 财政年份:
    2015
  • 资助金额:
    $ 37.11万
  • 项目类别:
Biomaterial Strategies for Tissue Engineering Pediatric Valves
组织工程儿科瓣膜的生物材料策略
  • 批准号:
    8315987
  • 财政年份:
    2011
  • 资助金额:
    $ 37.11万
  • 项目类别:
Tissue Engineering Strategies: Effects on Valvular Interstitial Cell Metabolism
组织工程策略:对瓣膜间质细胞代谢的影响
  • 批准号:
    8241919
  • 财政年份:
    2011
  • 资助金额:
    $ 37.11万
  • 项目类别:
Biomimetic micro-structured hydrogel scaffolds for tissue engineered heart valves
用于组织工程心脏瓣膜的仿生微结构水凝胶支架
  • 批准号:
    8663737
  • 财政年份:
    2011
  • 资助金额:
    $ 37.11万
  • 项目类别:
Tissue Engineering Strategies: Effects on Valvular Interstitial Cell Metabolism
组织工程策略:对瓣膜间质细胞代谢的影响
  • 批准号:
    8113636
  • 财政年份:
    2011
  • 资助金额:
    $ 37.11万
  • 项目类别:
Biomaterial Strategies for Tissue Engineering Pediatric Valves
组织工程儿科瓣膜的生物材料策略
  • 批准号:
    8178833
  • 财政年份:
    2011
  • 资助金额:
    $ 37.11万
  • 项目类别:
Biomimetic micro-structured hydrogel scaffolds for tissue engineered heart valves
用于组织工程心脏瓣膜的仿生微结构水凝胶支架
  • 批准号:
    8086246
  • 财政年份:
    2011
  • 资助金额:
    $ 37.11万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 37.11万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 37.11万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 37.11万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 37.11万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 37.11万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 37.11万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 37.11万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 37.11万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 37.11万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 37.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了